Psyence Biomedical Ltd. (NASDAQ: PBM) saw its shares advance by 7.59% to $5.81 today, driven by positive developments in a strategic collaboration. The upward momentum follows news that its partner, PsyLabs – a leading producer of purified psychedelic compounds – has successfully manufactured a GMP-aligned Ibogaine Total Alkaloid extract.
An authorized third-party laboratory confirmed that this high-purity extract complied with all microbiological safety standards for use in food. This collaboration continues to benefit Psyence BioMed, which purchased an ownership share in PsyLabs in 2024 and increased its holding in 2025.
A Significant Development in Psychedelic APIs
This accomplishment highlights the importance of Psyence BioMed’s ongoing investment in PsyLabs, which supports the creation of psychedelic active pharmaceutical ingredients (APIs) that are compliant and scalable for international markets.
PsyLabs is dedicated to improving its procedures even further in order to get even greater purity levels while maintaining compliance with GMP production regulations. As a key component of its pharmaceutical discovery endeavors, the business prioritizes sustainability, accuracy, and safety while extracting naturally derived raw materials.
Growth to Satisfy International Demand
The extraction branch of PsyLabs is enlarging its chemical production area in order to meet the increasing demands of the market. The production of high-purity Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs made from iboga and mushrooms will increase as a result of this project. Licensed research institutes and developers throughout the world will have access to these items, guaranteeing a consistent and ethical supply.
Progress in Clinical Research
Along with manufacturing advancements, Psyence BioMed has completed a service contract with the award-winning Australian Contract Research Organization (CRO) Southern Star Research Pty Ltd.
Psyence BioMed’s Phase IIb clinical study in Australia, which is assessing psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients, has advanced significantly with this agreement. Clinical monitoring, project administration, and data handling will all be under the supervision of Southern Star Research during the experiment.
Psyence BioMed is able to expedite trial progress without sacrificing quality or compliance since the transition from the prior CRO was carefully handled to guarantee a smooth continuation of operations.
Psyence BioMed is well-positioned to increase its market share in the quickly changing psychedelic treatments industry because of this combination of clinical development and manufacturing milestones.
Psyence Biomedical (PBM) Shares Rise on Strategic Collaboration News
Psyence Biomedical Ltd. (NASDAQ: PBM) saw its shares advance by 7.59% to $5.81 today, driven by positive developments in a strategic collaboration. The upward momentum follows news that its partner, PsyLabs – a leading producer of purified psychedelic compounds – has successfully manufactured a GMP-aligned Ibogaine Total Alkaloid extract.
An authorized third-party laboratory confirmed that this high-purity extract complied with all microbiological safety standards for use in food. This collaboration continues to benefit Psyence BioMed, which purchased an ownership share in PsyLabs in 2024 and increased its holding in 2025.
A Significant Development in Psychedelic APIs
This accomplishment highlights the importance of Psyence BioMed’s ongoing investment in PsyLabs, which supports the creation of psychedelic active pharmaceutical ingredients (APIs) that are compliant and scalable for international markets.
PsyLabs is dedicated to improving its procedures even further in order to get even greater purity levels while maintaining compliance with GMP production regulations. As a key component of its pharmaceutical discovery endeavors, the business prioritizes sustainability, accuracy, and safety while extracting naturally derived raw materials.
Growth to Satisfy International Demand
The extraction branch of PsyLabs is enlarging its chemical production area in order to meet the increasing demands of the market. The production of high-purity Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs made from iboga and mushrooms will increase as a result of this project. Licensed research institutes and developers throughout the world will have access to these items, guaranteeing a consistent and ethical supply.
Progress in Clinical Research
Along with manufacturing advancements, Psyence BioMed has completed a service contract with the award-winning Australian Contract Research Organization (CRO) Southern Star Research Pty Ltd.
Psyence BioMed’s Phase IIb clinical study in Australia, which is assessing psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients, has advanced significantly with this agreement. Clinical monitoring, project administration, and data handling will all be under the supervision of Southern Star Research during the experiment.
Psyence BioMed is able to expedite trial progress without sacrificing quality or compliance since the transition from the prior CRO was carefully handled to guarantee a smooth continuation of operations.
Psyence BioMed is well-positioned to increase its market share in the quickly changing psychedelic treatments industry because of this combination of clinical development and manufacturing milestones.
Most Popular
Psyence Biomedical (PBM) Shares Rise on Strategic Collaboration News
Expro Group (XPRO) Stock Surges On Record Margins
Carbon Revolution (CREV) Stock Rises Following Final Tranche of An Equity Funding
LGI Homes (LGIH) Shares Climb After Launch of New Atherstone Phase
Related Posts
Psyence Biomedical (PBM) Shares Rise on Strategic Collaboration News
Expro Group (XPRO) Stock Surges On Record Margins
Carbon Revolution (CREV) Stock Rises Following Final Tranche of An Equity Funding
LGI Homes (LGIH) Shares Climb After Launch of New Atherstone Phase